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Abstract 
The liver plays an essential role in maintaining glucose homeostasis, including by insulin-
mediated processes such as hepatic glucose output and uptake, as well in clearance of insulin 
itself. In Type 2 diabetes, the onset of hyperglycemia (itself a potent inhibitor of hepatic 
glucose output), alongside hyperinsulinemia, indicates the presence of hepatic insulin 
insensitivity. Increased hepatic glucose output is central to the onset of hyperglycemia, and 
highlights the need to target hepatic insulin insensitivity as a central component of 
antihyperglycemic therapy. The mechanisms underlying the development of hepatic insulin 
insensitivity are not well understood, but may be influenced by factors such as fatty acid 
oversupply and altered adipocytokine release from dysfunctional adipose tissue and increased 
liver fat content. Furthermore, although the impact of insulin insensitivity as a marker of 
cardiovascular disease is well known, the specific role of hepatic insulin insensitivity is less 
clear. The pharmacological tools available to improve insulin sensitivity include the 
biguanides (metformin) and thiazolidinediones (rosiglitazone and pioglitazone). Data from a 
number of sources indicate that thiazolidinediones in particular can improve multiple aspects 
of hepatic dysfunction, including reducing hepatic glucose output, insulin insensitivity and 
liver fat content, as well as improving other markers of liver function and the levels of 
mediators with potential involvement in hepatic function, including fatty acids and 
adipocytokines. The current review addresses this topic from the perspective of the role of the 
liver in maintaining glucose homeostasis, its key involvement in the pathogenesis of Type 2 
diabetes, and the tools currently available to reduce hepatic insulin insensitivity.  
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Introduction 
Type 2 diabetes is defined and diagnosed on the basis of hyperglycemia, although the extent 
of the metabolic dysfunction is much broader than glucose metabolism. Hyperglycemia is 
often conceived as resulting from a combination of impaired insulin action (reduced insulin 
sensitivity or ‘insulin resistance’) and a progressive loss of islet β-cell responsiveness [1]. 
However, glucose metabolism can be characterized as being abnormal in other ways, such as 
decreased glucose-mediated glucose disposal and loss of hepatic autoregulation of glucose 
concentrations [2, 3], suggesting more fundamental defects of liver and muscle metabolism 
may underlie what is loosely described as insulin insensitivity. A notable third contributor to 
hyperglycemia is glucose toxicity, exacerbating the defects defined above and thus 
magnifying any tendency to raised blood glucose levels [2–4].  While these abnormalities of 
tissue glucose metabolism are usually descriptively characterized as insulin insensitivity and 
glucose insensitivity, the more fundamental property of substrate flux (i.e. glucose mass 
action) will also contribute to determining the rate of glucose disposal in peripheral tissues 
[3].  
At steady-state glucose concentrations, glucose uptake peripherally must equal 
glucose input into the circulation (from liver, gut and kidney). If hepatic glucose output is 
abnormally high, glucose concentration in the blood will rise to the point at which 
concentration-driven glucose disposal compensates for the increased glucose input into the 
blood (which would occur even in the absence of insulin sensitive tissues). This situation may 
be complicated by down regulation of glucose transporters in metabolically active tissues 
such as the brain [5], which will decrease glucose clearance. At the same time, insulin-
sensitive tissues may also be responding less actively to insulin (partly as a result of glucose 
toxicity, but also partly through down-regulation of glucose transporters here too [5]), and 
hyperglycemia is exaggerated further.  
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One consequence of the need to maintain glucose disposal in such a situation is that 
glucose uptake will be increased secondary to the hyperglycemia in some tissues. However, 
few tissues can store glucose as glycogen, so in most cases, high concentrations of 
intracellular glucose derivatives simply drive glycolysis and other pathways of glucose 
metabolism. This may be of significance in driving intracellular abnormalities that lead to the 
acute and long term vascular abnormalities which characterize diabetes.  
Thus, even in the absence of primary peripheral insulin insensitivity, excessive 
inadequate controlled hepatic glucose output may lead to a chain of escalating metabolic 
disturbances with serious adverse consequences. The current review espouses the essential 
role of the liver in maintaining glucose homeostasis, discusses its key involvement in the 
pathogenesis of Type 2 diabetes and considers the tools currently available to reduce hepatic 
insulin insensitivity as a principal component of Type 2 diabetes therapy.  
 
Defining hepatic insulin insensitivity 
The term ‘insulin insensitivity’ is usually conceived as impaired insulin-stimulated 
glucose disposal in the periphery. This error has a number of origins, but is most firmly 
embedded in the concept that the major action of insulin is to assist disposal of ingested 
carbohydrate through uptake into skeletal muscle. This conceptual error has been enhanced by 
characteristic measurement of ‘insulin sensitivity’ by the glucose clamp technique, where the 
insulin concentrations often used are such that, in non-diabetic people, hepatic glucose output 
is almost fully suppressed, and any difference measured will be secondary to differences in 
the sensitivity of peripheral tissues to insulin (abnormalities of glucose concentration-driven 
metabolism being neutralized by the unchanging glucose concentrations of the clamp) [6]. 
There are two major problems with this concept. The first is the definitition of 
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‘sensitivity’ (or the more common, but less correct term ‘resistance’). In simple terms, a lower  
mass of insulin-sensitive tissue in the body should be associated with a decreased insulin 
response to a fixed dose of insulin. However, while it might be legitimate to say that the 
whole body response to insulin has decreased, it cannot be said that the responsiveness of 
skeletal muscle has changed. Although correcting insulin dose for body weight (as is usually 
done), might be thought to compensate for this, skeletal muscle mass (the major component of 
body weight in most people) does not vary directly in proportion to it. Even if the insulin dose 
is given per kilogram of skeletal muscle (or its surrogate fat free mass), problems of 
interpretation of the meaning of insulin sensitivity still arise.  
Secondly, the concept fails to grasp the idea of insulin insensitivity in the context of 
the broader metabolic, tissue and organ dysfunction present in Type 2 diabetes — in 
particular, hepatic dysfunction. Insulin-stimulated glucose disposal in the periphery is just one 
component of insulin insensitivity, which also encompasses insulin-mediated processes in the 
liver, such as hepatic glucose output (HGO) and uptake (HGU), as well as clearance of insulin 
itself. 
 The failure of islet β-cells to compensate adequately for impaired insulin-stimulated 
glucose disposal is one of the principle mechanisms underlying the onset of hyperglycemia 
and overt Type 2 diabetes [7,8]. However, an accompanying rise in hepatic glucose output 
due to hepatic insulin insensitivity (at least in part) is a central component. In otherwise 
healthy individuals without diabetes, hyperinsulinemia would be expected to suppress HGO 
and lower blood glucose. In Type 2 diabetes, however, the onset of hyperglycemia (itself a 
potent inhibitor of HGO), together with hyperinsulinemia, indicates the presence of hepatic 
insulin insensitivity [9,10] (Figure 1). It has been postulated that hepatic insulin insensitivity 
(and the accompanying increase in HGO) is secondary to peripheral insulin insensitivity  
i.e. a compensatory response to restore peripheral glucose uptake in the presence of peripheral 
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insulin insensitivity. However, recent evidence from studies in gene knockout mice supports 
the idea that the liver may also be a primary site of insulin insensitivity [11], suggesting the 
presence of intrinsic hepatic dysfunction in the pathogenesis of Type 2 diabetes. In either 
case, as increased HGO is central to the onset of hyperglycemia, it highlights the need to 
target hepatic insulin insensitivity as a central component in treating hyperglycemia.  
 
The liver and glucose homeostasis in the normal state 
In the healthy, non-diabetic individual, plasma glucose levels are a tightly controlled balance 
between glucose production and glucose utilization. The liver is responsible for providing 
90% of the glucose to both insulin-insensitive and insulin-sensitive tissues in the fasting state 
[12], with over two-thirds of this being utilized by non-insulin-sensitive tissues (principally 
the central nervous system [CNS]), and the remainder by insulin-sensitive tissues (principally 
skeletal muscle) [13]. The liver is therefore the primary organ responsible for maintaining 
sufficient glucose levels and preventing hypoglycemia in the fasting state.  
Glucose production is determined in approximately equal measure by the rates of 
gluconeogenesis and glycogenolysis in the immediate fasting state, although the role of 
hepatic glycogen becomes negligible with more prolonged fasting. Recycling of muscle 
glycogen via intermediary metabolism (the Cori cycle) serves to maintain the glucose levels 
necessary for the CNS [14]. Under fasting conditions where insulin levels are low, the 
principle hormonal mechanism maintaining glycemia involves stimulation of gluconeogenesis 
and glycogenolysis by basal levels of glucagon, although other hormonal and neural factors 
may also be involved. In the prandial state, on the other hand, the meal-related increase in 
insulin concentration (producing a high insulin/glucagon ratio) is the principle stimulus to 
suppress HGO by promoting glycogen synthesis and inhibiting glycogenolysis and 
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gluconeogenesis [15]. 
The dose−response curve relating plasma insulin to HGO reveals that the liver is 
sensitive to small increases in portal vein insulin concentrations [10] (Figure 1). The 
dose−response curve of insulin’s action on peripheral glucose uptake, however, shows it to be 
less effective in the periphery with EC50 values double those for HGO [16]. Consequently, 
with low physiological increments in plasma insulin, the liver is the primary determinant of 
whole body glucose homeostasis. In both animal and human studies, low concentrations of 
insulin appear to inhibit HGO acutely through a rapid direct effect on glycogenolysis in the 
liver [17,18]. 
Again, it should be emphasized that non-hormonal mechanisms also play a key role in 
regulating physiological glucose levels in the prandial state. In response to physiological 
hyperglycemia, net HGO can be attenuated by 60–90% in the presence of basal 
insulin/glucagon concentrations [2]. Furthermore, non-esterified fatty acids (NEFA) can also 
inhibit insulin- and glucose-induced stimulation of muscle glucose uptake and suppression of 
HGO, as well as resetting hepatic autoregulation [19] and increasing the contribution of 
gluconeogenesis to HGO [20].  
An indirect effect of insulin on HGO via inhibition of glycogenolysis/gluconeogenesis 
has been demonstrated in animals and humans –– as expected this occurs more slowly and at 
higher insulin concentrations [17,18,21]. While it has been suggested that this indirect effect 
(which may occur via insulin-mediated inhibition of lipolysis in adipose tissue and reduction 
of the plasma NEFAs, or other adipose tissue, neural, pancreatic α-cell or muscle-derived 
effects) may be the major component of the suppressive effect of insulin on HGO in non-
diabetic individuals, studies looking at the portal insulin signal in dogs suggest that direct 
effects are at least of equal significance and dominate in the basal state [22]. In fact, a recent 
study in dogs suggests that the direct effects are predominant [23]. Furthermore, in liver-
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specific insulin receptor knockout mice, even high-dose insulin fails to suppress HGO. This 
indicates that both direct and indirect effects of insulin require an intact insulin-signalling 
pathway in the liver [24,25]. By contrast, muscle-specific insulin receptor knockout mice 
maintain normal fasting and post-challenge glucose homeostasis [25]. 
 
Hepatic glucose uptake 
In healthy non-diabetic individuals, approximately one-third of an oral glucose load is taken 
up by muscle and fat, one-third by the liver (via insulin-dependent and independent 
mechanisms) and one-third by other non-insulin-dependent tissues [26]. This distribution, 
combined with the liver’s role in meal-related suppression of endogenous glucose production, 
emphasizes the central role that the liver plays in determining the extent of postprandial 
excursion of blood glucose concentrations, in addition to the regulation of fasting levels in the 
non-diabetic individual [26].  
HGU (measured as splanchnic glucose uptake in humans) is less sensitive to insulin 
relative to its effects on HGO and less sensitive than peripheral glucose uptake. This suggests 
that different insulin signalling mechanisms exist within the liver [27]. However, as with the 
effects of insulin on HGO, approximately 50% of the effect of insulin on HGU appears to be a 
direct effect on the liver (associated with an increase in glycogen storage) and the remaining 
50% an indirect effect (associated with increases in glycolysis and glucose oxidation) [28]. 
It should be mentioned that many other factors influence the effectiveness of insulin to 
control glucose uptake in the liver — in particular, hormone-independent autoregulation by 
glucose itself, which is synergistic with the effects of insulin, such that hyperinsulinemia by 
itself is relatively ineffective at promoting HGU and equally, the liver has a reduced ability to 
respond to hyperglycemia when insulin is deficient. However, unlike HGO, glucose uptake 
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generally only occurs in response to supraphysiological rather than physiological glucose 
levels. Whereas the glucose transporters (GLUT-1 and GLUT-2) in the liver do not depend on 
insulin for their translocation, insulin is probably involved in the autoregulatory response, 
through its ability to maintain glucokinase and glycogen synthase activity in the liver [2]. 
Fatty acids have also been shown to impair insulin-mediated HGU in healthy 
individuals [29]. In addition, studies in dogs suggest that high portal glucose levels relative to 
the periphery impart an inhibitory signal in non-hepatic tissues, particularly skeletal muscle. 
This reduces peripheral glucose disposal and thus directs glucose to the liver [30]; this effect 
appears to be neurally mediated. Furthermore, it has also been hypothesized that, in response 
to insulin, a factor is released from the liver that stimulates glucose uptake in skeletal muscle. 
In order for insulin to produce this effect, a parasympathetic permissive reflex that signals the 
presence of feeding must be present [31]. Mechanisms such as these may at least partially 
explain the differences in dose−response relationships between HGO in the liver and glucose 
disposal in the periphery. Finally, hypothalamic lipid-sensing via brain insulin receptors is 
proposed to regulate hepatic glucose metabolism via the activation of vagal efferent fibres that 
supply the liver [32]. 
 
Key signaling pathways involved in glucose homeostasis in the liver 
Binding to the glucagon receptor on hepatocytes activates the serine/threonine kinase 
protein kinase A (PKA) causing phosphorylation and activation of glycogen phosphorylase 
kinase (GPK) and subsequently glycogen phosphorylase (GP), thus activating glycogenolysis. 
An increase in intracellular cyclic AMP also induces gluconeogenesis enzymes 
(phosphoenolpyruvate carboxykinase [PEPCK] and glucose-6-phosphatase [G6Pase]) via 
induction of peroxisome proliferator activated receptor-γ coactivator 1α (PGC-1α) [for 
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review see 33]. It should be emphasised, however, that under fasting conditions (potentially 
hypoglycemic conditions, in particular), non-hormonal mechanisms (principally hepatic 
autoregulation by glucose itself) are capable of supplying a significant proportion (up to 50%) 
of the body’s glucose requirements via enhancement of both glycogenolysis, glucose cycling 
and eventually gluconeogenesis) [2].  
The pathways involved in insulin signalling in the liver are highly complex, involving 
hundreds of signaling molecules  (reviewed in detail elsewhere [34,35], and thus a myriad of 
potential points for modulation and interaction with other pathways, such as those involved in 
glucose autoregulation. Insulin signalling processes also appear to differ in different tissues. 
The first key component in the signalling process is the insulin receptor itself and the 
associated intracellular insulin receptor substrate (IRS) proteins [35]. The IRS-2 subtype 
appears to play a more prominent role in the liver, whereas the IRS-1 subtype may be more 
important in skeletal muscle [36], and these two proteins have different capacities to interact 
with downstream signalling elements [37]. Within the liver, IRS-1 has been more closely 
linked with glucose homeostasis, whereas IRS-2 may be more closely liked with lipid 
metabolism [38], although surprisingly, liver-specific knockout of IRS-2 in mice does not 
appear to impair hepatic glucose and lipid metabolism [39]. The second key component 
involves the activation of the phosphatidylinositol 3-kinase (PI3K) pathway, which appears to 
be crucial for insulin’s metabolic actions in vivo in the liver [35,40] After PI3K activation, the 
specific regulation of glucose and lipid homeostasis by insulin in the liver diverges —  PI3K-
dependent activation of Akt (also known as protein kinase B [PKB]) appears to regulate 
factors involved in gluconeogenesis, whereas PI3K-dependent activation of atypical forms of 
protein kinase C appears to regulate factors involved in lipogenesis [40]. For instance, a 
pathway downstream of Akt leads to inactivation of phosphorylase, activation of glycogen 
synthase, and stimulation of glycogen synthesis, thus counteracting the effects of glucagon 
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[41], 
In addition to acute effects on metabolic processes, insulin can also induce changes in 
gene transcription in the liver down-stream of the PI3K pathway [for reviews see 42, 43]. 
Insulin can influence the expression of over 150 genes — this occurs via key transcription 
factors, such as FOXO1 that inhibits expression of PEPCK and G6Pase and inhibits 
gluconeogenesis), sterol-response element binding proteins (SREBPs) that primarily regulate 
genes involved in lipid synthesis), and specificity protein 1 (Sp1) that regulates genes for 
insulin receptors and leptin). 
 
Insulin clearance in the liver 
The liver is also the primary site of insulin clearance, with approximately 50% of portal 
insulin being removed during first-pass transit, thus limiting hyperinsulinemia in the 
periphery [for review see 44]. As such, mean insulin concentrations in the portal vein are 
approximately twice as high as in the periphery and insulin pulse amplitude can be up to ten 
times higher [45]. Most uptake is a receptor-mediated process and prolonged increases in 
portal insulin levels result in reduced clearance due to receptor down-regulation [31]. Insulin 
sensitivity and clearance have been found to be directly and linearly correlated [46]. Uptake 
and degradation are also under the influence of mediators, such as NEFA (which has an 
inhibitory effect) [47]. 
 
Insulin and hepatic fat metabolism 
A further direct action of insulin in the liver involves the metabolism of hepatic fat and 
production of triglyceride-rich very low-density lipoprotein (VLDL) [for review see 48]. 
Rates of hepatic VLDL secretion by the liver depend largely upon the partitioning of 
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preformed fatty acids between oxidation and esterification, and the retention or secretion by 
the liver of synthesized triglycerides [48]. Insulin acutely inhibits VLDL production and this 
effect may be modified by nutritional state — insulin secretion in a fed state may stimulate 
hepatic VLDL-triglyceride secretion, whereas insulin secretion after a sufficiently long fast 
may actually inhibit VLDL secretion [49]. This may play a role in regulating postprandial 
lipemia, although as with glucose, this can only be fully understood in the context of the 
peripheral tissues involved, principally adipose tissue and skeletal muscle. Disturbances in fat 
metabolism in the liver (possibly due to oversupply of NEFA or reduced adiponectin levels), 
leading to fatty infiltration (and thus fatty liver) may be an important factor in the 
development of hepatic insulin insensitivity (see below) and diabetic dyslipidemia 
(hypertriglyceridemia). 
 
The liver as a central organ in the pathogenesis of diabetes 
It is clear from the sections above that the liver and its response (either direct or indirect) to 
insulin in particular, are critically involved in a complex set of processes that directly control 
glucose levels also affected by glucose metabolism in the periphery (Table 1). In Type 2 
diabetes, the excessive rate of HGO is generally considered to be the major abnormality 
responsible for the elevated fasting plasma glucose (FPG) concentration and the defect in its 
suppression a primary factor underlying postprandial hyperglycemia [50]. This may be 
important to help to overcome decreased peripheral insulin sensitivity through the 
compensatory mass action effect of hyperglycemia. However, reduced HGU may also 
contribute to the fasting hyperglycemia of Type 2 diabetes by an insulin-dependent 
mechanism and by altering glucose sensing within the hepatocyte (by disturbing 
autoregulation), thereby disrupting the regulation of glucose release [4]. This attenuation of 
glucose sensing in the liver only serves to put further burden on active hormone-dependent 
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processes in the struggle to restore adequate glucose homeostasis in Type 2 diabetes.  
 
Hepatic insulin insensitivity in diabetes 
In Type 2 diabetes, the onset of hyperglycemia (itself a potent inhibitor of HGO), alongside 
normo- or hyperinsulinemia, indicates the presence of hepatic insulin insensitivity. Severe 
hepatic insensitivity to insulin is observed at all plasma insulin concentrations throughout the 
physiological range [10]. The dose−response curves for both peripheral glucose uptake and 
HGO are shifted by an equivalent amount to the right in people with Type 2 diabetes, 
showing that both hepatic and peripheral insulin insensitivity are equally affected and that the 
higher relative sensitivity of the liver to insulin is maintained [16]. Nevertheless, recent 
studies in rodents suggest that insulin signalling alterations in insulin-resistant liver may be 
distinct from those reported for insulin-resistant skeletal muscle in animals and humans [51]. 
In addition to reduced suppression of HGO, hepatic insulin insensitivity also presents 
as a reduction in HGU. Due to the presence of marked insulin insensitivity in muscle, the 
relative contribution of HGU to overall glucose disposal is greater in people with diabetes, 
particularly while absolute insulin concentrations are raised. People with Type 2 diabetes are 
also insensitive to the acute inhibitory effect of insulin on VLDL production in the liver and 
insulin clearance rates are decreased [44].  
The mechanisms underlying the development of hepatic insulin insensitivity are not 
well understood. It has been postulated that, due to the high sensitivity of the liver to insulin 
relative to peripheral tissues, small deficits in the β-cell response that occur early in the 
pathogenesis of diabetes could be responsible for increases in HGO [50]. This in turn could 
lead to glucose toxicity-induced peripheral insulin insensitivity [3] and compensatory 
hyperinsulinemia. Furthermore, it has been suggested that hepatic insulin insensitivity may be 
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the primary event in the development of whole-body insulin insensitivity associated with 
increased adiposity. Studies in dogs by Kim and colleagues [52] showed that increases in 
adiposity produce only a moderate defect in peripheral insulin sensitivity, but can produce a 
complete failure of insulin to suppress glucose production during a hyperinsulinemic-
euglycemic clamp. 
Whereas some authors suggest that people with Type 2 diabetes are primarily resistant 
to the direct hepatic suppressive effect of insulin (possibly mediated via glycogenolysis), with 
intact indirect peripherally mediated suppression of glucose production [53], others report that 
both indirect and direct effects are impaired with the greatest impairment seen in the indirect 
extrahepatic process, especially at high insulin levels [54]. In concert with these findings, 
there is evidence for both increased gluconeogenesis and accelerated glycogenolysis 
associated with increases in HGO [55].  
 The presence of excess liver fat is emerging as a key factor involved in the 
development of hepatic insulin insensitivity. Liver fat correlates with whole body and hepatic 
insulin resistance in people with and without diabetes [56] and also correlates with high 
insulin requirements [57]. Reducing hepatic fat content could therefore be a key target for 
therapies aimed at improving hepatic insulin sensitivity. Furthermore, the fatty liver is 
associated with overproduction of multiple cardiovascular risk factors (including PAI-1, C-
reactive protein [CRP], fibrinogen, in addition to glucose and lipids) [58], and is therefore 
also a target for lowering cardiovascular risk. However, the causes of fat accumulation in the 
liver remain poorly understood. Changes in adipose tissue function resulting in NEFA 
oversupply and alterations in adipocytokine release (especially reduced adiponectin) are 
possible candidates [58]. For instance, adiponectin level is negatively associated with liver fat 
content and HGO in people with type 2 diabetes [59].  
Certainly, several adipose tissue-associated factors appear to contribute to the complex 
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regulation of glucose homeostasis in the liver and abnormal circulating levels of NEFA, 
adiponectin and resistin (among others) are observed in people with diabetes. In particular, 
NEFAs are known to enhance HGO, impair insulin-mediated HGU and have been implicated 
in the development of both insulin insensitivity and Type 2 diabetes [29]. Elevated plasma 
NEFAs induce hepatic insulin insensitivity by inhibiting the insulin signal transduction 
system and abnormal insulin-mediated suppression of plasma NEFA appearance rate may be 
an early defect in those who develop Type 2 diabetes [60]. Furthermore, in the presence of 
hepatic insulin insensitivity, hepatic lipogenesis is increased. This raises VLDL production, 
which increases NEFA from adipose tissue leading to further escalation of VLDL production 
and an ensuing vicious circle.  
In addition, people with Type 2 diabetes have characteristics of an inflammatory 
condition with increased levels of pro-inflammatory cytokines interleukin-6 (IL-6), 
interleukin-1 (IL-1), tumor necrosis factor-α (TNF-α) and liver-derived acute-phase reactants, 
such as CRP and serum amyloid A (SAA) [for review see 15]. Subclinical chronic 
inflammation might be an important pathogenic factor in the development of insulin 
insensitivity and IL-6 can inhibit insulin receptor signal transduction in hepatocytes in culture 
and in livers of mice injected with IL-6, whereas TNF-α antagonizes insulin receptor 
signalling by promoting serine phosphorylation of IRS-1 and IRS-2. 
 
Hepatic dysfunction, insulin insensitivity and CVD 
Insulin insensitivity is now well established as a risk marker for cardiovascular disease 
(CVD). A number of cross-sectional studies have reported an association between insulin 
insensitivity and CVD risk in people with or without Type 2 diabetes and, more recently, 
longitudinal studies have added more weight to this association [61,62]. It is possible that 
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interventions that improve insulin sensitivity may improve CVD outcomes more than 
expected from glucose-lowering alone, as suggested with metformin in the UKPDS [63]. 
However, the recently reported results of the PROactive study have failed to confirm this 
expectation emphatically [64]. 
As part of the normal physiological maintenance of glucose homeostasis, 
compensatory fasting hyperinsulinemia is an inevitable consequence of underlying insulin 
insensitivity in muscle and adipose tissue, as long as sufficient residual islet β-cell function 
remains, especially in the earlier stages of Type 2 diabetes. However, not all tissues share the 
defect in insulin action, thus leading to the potential adverse impact of the compensatory 
hyperinsulinemia on tissues that remain normally insulin sensitive [65]. Many CVD risk 
factors, such as a dysregulated lipoprotein profile, endothelial dysfunction, procoagulant 
activity and vessel wall inflammation have been postulated as being secondary to this 
compensatory hyperinsulinemia [65]. Such a relationship may appear to be supported by a 
number of epidemiological and observational studies in which fasting hyperinsulinemia has 
been associated with increased CVD risk and mortality. However, the complexity of the 
relationship between hyperinsulinemia, insulin insensitivity and other CVD risk factors makes 
these factors hard to separate [for review see 65] and the magnitude of the relationships 
themselves is often too small to attribute causation with any confidence. 
How much of this increased CVD risk is attributable specifically to hepatic insulin 
insensitivity remains undetermined. The relationship persists where measurements primarily 
assess hepatic insulin sensitivity (for example, using homeostasis model assessment [HOMA], 
see below), although this may mirror peripheral insulin sensitivity [62, 66]. Furthermore, 
CVD is associated with FPG level [67], which (as mentioned above) is determined primarily 
by glucose homeostasis in the liver. Certainly, components of diabetic dyslipidemia, which 
are themselves risk factors for CVD [68], can be attributed to hepatic insulin insensitivity. For 
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instance, insulin insensitivity in the liver will be a major determinant of both hepatic 
triglyceride accumulation and plasma triglyceride levels [69]. In addition, liver fat content is 
an independent marker of myocardial function and reduced coronary functional capacity [70]. 
Further support for the potential clinical impact of hepatic dysfunction and insulin 
insensitivity comes from measurements of CRP. This primarily liver-derived factor is a 
marker of subclinical inflammation that is independently related to insulin sensitivity [71], to 
increased risk of development of Type 2 diabetes [72] and to increased cardiovascular event 
risk, with an effect size exceeding that of LDL-cholesterol in the at-risk population [73].  
 
Assessing hepatic insulin resistance in clinical trials 
To evaluate the effects of insulin-sensitizing agents on insulin-mediated processes in the liver, 
it is necessary to measure hepatic insulin sensitivity reliably. This requires the quantification 
of parameters related to HGO and HGU occurring in vivo during fasting, during low-dose 
hyperinsulinemic clamps, or using other dynamic tests. The use of glucose tracers, 
sophisticated tissue-specific techniques (for example, positron emission tomography), proper 
(non-trivial) calculations and a significant experimental expertise are necessary [29,74,75]. In 
addition, other hormones such as glucagon, play a fundamental role in modulating HGO 
under some conditions. Accordingly, their effects need to be taken into account when 
interpreting study data or they may confound the calculation of a reliable index of hepatic 
insulin sensitivity [76]. 
In the absence of complex methodologies, hepatic insulin sensitivity can be 
extrapolated from the currently used methods to assess whole body insulin sensitivity, but this 
requires the assumption that the defect in insulin sensitivity in the liver and peripheral tissues 
is equivalent [77]. The glucose infusion rate during the steady-state phase of the glucose 
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clamp is usually achieved after 2–3 hours and assessed at sustained levels of marked 
hyperinsulinemia. Given that HGO is suppressed at these levels (even in insulin-insensitive 
individuals), differences in the glucose infusion rate largely reflect peripheral glucose uptake 
rather than hepatic balance. The other widely used test is the intravenous glucose tolerance 
test (IVGTT), but here too, the elevated blood glucose and insulin levels following the 
administration of the glucose bolus are likely to shut down HGO quickly [78]. Therefore 
differences in insulin sensitivity, measured over 3 hours again reflect mostly the peripheral 
processes.  
Indeed, for calculations of HGO, tracers [79] and specific mathematical modelling 
[80] must be exploited. Problems of tracer methodology, the relative sensitivity of hepatic and 
peripheral insulin responsiveness and the narrow window between normal HGO and complete 
HGO suppression, make construction of reliable insulin dose–response curves for this 
parameter difficult. 
The oral glucose tolerance test (OGTT) and recently the meal test have been widely 
used for their simplicity and because they mimic the every-day handling of nutrients. These 
tests appear to involve the liver in a more pronounced way, perhaps because of their slow 
dynamics. However, the liver is sensitive to the rate of glucose absorption and the lack of any 
method to quantify this source of glucose with sophisticated double-tracer techniques [81] 
means that changes found in an OGTT reflect peripheral rather than hepatic sensitivity, as 
well as β-cell dysfunction.  
Finally, surrogate markers of insulin sensitivity can be calculated when just fasting 
glucose and insulin are available. HOMA appears to be a reasonable index for assessing 
insulin sensitivity within studies when a single insulin assay is used [82]. However, 
relationships of insulin sensitivity versus other variables are generally weak using this method 
[76]. The quick insulin sensitivity check index (QUICKI) is a log transformation of HOMA to 
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yield directly an insulin sensitivity index [83]. Since the liver is playing the fundamental role 
in glucose homeostasis in basal fasting conditions, these indices (HOMA, QUICKI) can be 
assumed with reasonable approximations to be markers of hepatic insulin sensitivity rather 
than peripheral insulin sensitivity. The accuracy of HOMA may be particularly limited in 
people with hyperglycemia [77]; nevertheless, it has become one of the standard tools used in 
large-scale trials, given the advantages of being simple and relatively inexpensive. 
Recently, a study from the De Fronzo group [84] showed that, in subjects with impaired 
fasting glucose and/or impaired glucose tolerance, as well as in normo-tolerant individuals, 
the glucose clamp-derived total glucose disposal (peripheral insulin sensitivity) strongly 
correlated with OGTT-derived dynamic measurements of insulin sensitivity (Matsuda’s 
ISIcomp [85], Stumvoll’s MCRest [86], and Mari’s OGIS [87]), while HOMA correlated more 
strongly with the basal hepatic insulin resistance, assessed during the titrated glucose infusion. 
This study further confirms that surrogate fasting insulin resistance indices, such as HOMA or 
QUICKI, are indicative of hepatic insulin resistance. 
The effect of oral glucose-lowering agents on hepatic function 
Currently available glucose-lowering drugs with some effect on insulin sensitivity include the 
biguanides (principally metformin) and the thiazolidinediones (pioglitazone and 
rosiglitazone). In addition, some studies have used troglitazone, which is no longer clinically 
available. Thiazolidinediones are agonists for the peroxisome proliferator-activated receptor 
gamma (PPARγ), which regulates multiple genes controlling carbohydrate and lipid 
metabolism [88].  
 
Metformin 
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The molecular mechanisms that explain the clinical effects of metformin remain poorly 
understood, although it seems clear that biguanides can inhibit the early steps of 
gluconeogenesis and, in higher concentrations, this explains metformin’s propensity to cause 
lactic acidosis. In the basal, post-absorptive state, the improvement of fasting hyperglycemia 
with metformin is mostly due to a decrease of the elevated HGO [for review see 89], resulting 
from direct inhibition of gluconeogenesis and possibly glycogenolysis in the liver. A recent 
systematic review of clinical studies by Natali and Ferrannini suggests that, whereas 
metformin can enhance insulin suppression of HGO and FPG clearance (assessed using tracer 
glucose techniques), it does not appear to improve peripheral glucose disposal (assessed using 
the euglycaemic–hyperinsulinaemic clamp) [90]. 
Although its cellular mechanism of action in the liver remains poorly defined, a recent 
study demonstrates that metformin’s effects in the liver include insulin receptor activation, 
followed by selective IRS-2 activation and increased glucose uptake via increased GLUT-1 
translocation [91]. Another key component may be stimulation of AMP-activated protein 
kinase (AMPK), which plays a critical role in systemic energy balance and may mediate the 
activity of adipokines in regulating glucose and lipid homeostasis [92]. Activation of AMPK 
appears to be necessary for metformin’s inhibitory effect on glucose production by 
hepatocytes [93], and metformin cannot lower blood glucose levels in mice that lack hepatic 
LKB1, which is an upstream kinase in the AMPK cascade [94, 95].  
Some reported effects on peripheral glucose disposal may reflect overall 
improvements in glycemia (decrease in glucose toxicity) and metformin has been shown to 
facilitate glucose transporter trafficking in peripheral tissues. In the fed condition, metformin 
may also be affecting gut uptake of nutrients. However, an effect on gluconeogenesis in the 
fasting state would be expected to restore towards normal hepatic autoregulation of glucose 
handling. This effect might be interpreted as improved insulin responsiveness in a low-dose 
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insulin clamp. 
 
Thiazolidinediones 
Evidence from animal studies shows that the thiazolidinediones improve hepatic insulin 
sensitivity, as well as peripheral insulin sensitivity. Thus, administration of thiazolidinediones 
with a low dose of insulin restores HGO towards normal levels in streptozotocin-induced 
diabetic rats [96]. Similarly, whereas recombinant human growth hormone (rhGH) inhibits 
suppression of HGO in rats, this is restored when troglitazone is co-administered with rhGH 
[97]. Furthermore, troglitazone selectively decreased HGO in a spontaneous, non-obese, 
normolipemic rat model of Type 2 diabetes independently of its action on peripheral insulin 
sensitivity [98]. In addition, studies using isolated perfused liver from a rat model of Type 2 
diabetes suggest that pioglitazone can directly increase hepatic insulin sensitivity in situ in the 
liver [99]. At the hepatic cellular level, PPARγ activation decreases the expression of several 
of genes involved in gluconeogenesis (PEPCK, pyruvate carboxylase, and glucose-6-
phosphatase) [100], and also upregulates other genes such as hormone sensitive lipase (via 
Sp1), which plays an important role in lipid mobilisation and may be involved in the 
development of insulin insensitivity when deficient [101]. Recent studies also suggests that 
thiazolidinediones may activate AMPK directly in the liver and also have direct anti-
inflammatory effects in hepatocytes [102,103].  
The primary site of thiazolidinedione action, however, remains controversial. PPARγ 
is expressed abundantly in adipose tissue, whereas expression is low in liver and muscle. This 
in itself might suggest that the hepatic effects are secondary to changes in NEFA or 
triglyceride metabolism. Data from knockout mouse models shed some light on this. Selective 
knockout of PPARγ in adipose tissue causes fatty liver, increased liver gluconeogenesis and a 
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decreased response to insulin action on HGO, but does not induce insulin insensitivity in 
muscle [104]. This could either indicate an indirect adipose tissue-related influence of PPARγ 
activation on the liver, or a direct effect on liver, which might seem less likely given the low 
level of PPARγ expression in the liver (Figure 2). However, treatment with a 
thiazolidinedione in these animals (with preserved liver PPARγ) improves insulin suppression 
of HGO, supporting the presence of a direct activation component in the liver itself. Similarly, 
muscle PPARγ-deficient mice also develop hepatic insulin insensitivity, but not muscle 
insensitivity, and this is accompanied by increased adiposity — these mice also respond to 
thiazolidinediones [105]. These studies suggest that thiazolidinediones improve insulin 
sensitivity by direct actions on tissues other than skeletal muscle (i.e. adipose tissue and 
possibly liver) and that, in the absence of adipose tissue, the liver becomes the primary site of 
thiazolidinedione action [88]. This is supported by studies in lipoatrophic mice, where 
inactivation of liver PPARγ reduces hepatic steatosis, but worsens the hyperlipidemia, 
triglyceride clearance and interestingly muscle insulin sensitivity, in addition to abolishing the 
hypoglycemic and hypolipidemic effects of rosiglitazone [106]. Furthermore, a recent study in 
liver-specific insulin receptor knockout mice suggests that, whereas thiazolidinediones 
probably improve some lipid parameters even in the presence of absolute hepatic insulin 
insensitivity, both metformin and thiazolidinediones require an operating insulin-signalling 
system in the liver for their effects in glucose homeostasis [107].  
Studies using the euglycemic insulin clamp and frequently sampled IVGTT in people 
with Type 2 diabetes have extended insights on the mechanism of action of thiazolidinediones 
to a more clinically relevant level. The systematic review by Natali and Ferrannini suggests 
that, unlike metformin, thiazolidinediones improve peripheral glucose disposal in addition to 
enhancing insulin suppression of HGO and FPG clearance [90]. Pioglitazone therapy in 
people with Type 2 diabetes decreases both fasting and postprandial plasma glucose levels by 
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improving whole-body insulin sensitivity and, more specifically, both insulin-mediated 
suppression of HGO and peripheral glucose uptake in a dose-dependent manner [6,108,109]. 
Recent studies suggest that both pioglitazone and rosiglitazone decrease FPG via an inhibition 
of gluconeogenesis in the liver [110, 111]. Furthermore, pioglitazone also augments 
splanchnic (i.e. hepatic) glucose uptake [109] and dose-dependently enhances islet β-cell 
function [108]. Recent studies also show that rosiglitazone can increase hepatic insulin 
clearance in people with type 2 diabetes [112, 113]. 
A shift of fat distribution from visceral to subcutaneous adipose depots after 
pioglitazone treatment is associated with improvements in hepatic and peripheral tissue 
sensitivity to insulin [114]. Indeed, pioglitazone treatment in Type 2 diabetes decreases 
hepatic fat content [109]. This could be secondary to decreased NEFA supply and, as noted 
above, might itself reverse improved hepatic glucose metabolism and thus appear to reverse 
hepatic insulin insensitivity. These studies also suggest a role for adipokines in the 
mechanism of action of thiazolidinediones. Thus, the increase in plasma adiponectin 
concentration seen after thiazolidinedione therapy may play an important role in reversing the 
abnormality in hepatic fat mobilization and the hepatic/muscle insulin insensitivity in people 
with Type 2 diabetes [59]. Recent studies in adiponectin-deficient knockout mice suggest that 
activation of AMPK may be involved in the adiponectin-dependent effects of 
thiazolidinediones in the liver  [115, 116], Rosiglitazone has also been shown to increase the 
expression of the adiponectin ADIPOR2 receptor subtype in mouse hepatocytes, which may 
increase liver sensitivity to adiponectin and synergize with the adiponectin-raising effects 
[117]. On the other hand, a decrease in plasma resistin is positively correlated with the 
decrease in hepatic fat content and improvement in hepatic insulin sensitivity seen with 
pioglitazone [118].  
These studies also provide head-to-head comparisons of thiazolidinediones with 
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metformin, revealing differences in pattern of action. Recently, Tiikkainen and colleagues 
[112] found that metformin and rosiglitazone both improved hepatic insulin sensitivity in 
people with Type 2 diabetes, though to a different extent. However, only rosiglitazone 
treatment produced a reduction in liver fat content. Furthermore, only rosiglitazone increased 
peripheral glucose uptake and PPARγ, lipoprotein lipase and adiponectin expression in 
adipose tissue.  
Further support for the hepatic action of thiazolidinediones comes from their effects 
on levels of CRP. Thiazolidinediones significantly reduce CRP levels in people with the 
metabolic syndrome [119] and in those with Type 2 diabetes [120] and rapidly improves both 
CRP and serum amyloid A (SAA) levels in healthy individuals [121]. Improving glycemic 
control with sulfonylureas, however, does not influence CRP levels [122]. While metformin 
can also reduce CRP levels by 30% in diabetes, it is only half as effective as troglitazone over 
4 months of treatment [120] and not all studies have been able to demonstrate an effect of 
metformin on CRP [123]. Furthermore, a recent meta-analysis of four 1-year studies with 
pioglitazone in people with Type 2 diabetes shows a consistent reduction in alanine 
aminotransferase (ALT) levels (a marker of fatty liver disease [124]), suggesting potential 
beneficial effects on liver function, whereas metformin showed small increases or decreases 
and gliclazide showed consistent increases [125]. 
 
Effects on insulin sensitivity in clinical trials 
Several short-term studies have confirmed the beneficial effects of the thiazolidinediones in 
improving insulin sensitivity as measured using the HOMA, a test which, as described above, 
primarily assesses hepatic insulin sensitivity. In a 12-week study in 330 people with Type 2 
diabetes, troglitazone significantly improved insulin sensitivity and lowered fasting plasma 
insulin levels compared with placebo [126]. Similarly, rosiglitazone significantly improved 
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insulin sensitivity among people with Type 2 diabetes treated for 12 weeks [127] and 26 
weeks [128]. Several studies have also demonstrated an improvement with pioglitazone either 
as monotherapy or in combination with a sulfonylurea or metformin. In a 16-week study in 
people with Type 2 diabetes, pioglitazone therapy (30 or 45 mg/day) resulted in significant 
reductions in fasting serum insulin levels and increased insulin sensitivity versus placebo 
[129]. Pioglitazone monotherapy significantly improved insulin sensitivity and improved islet 
β-cell function among people with Type 2 diabetes treated for 23 weeks in a study that also 
demonstrated a reduction in several risk markers for CVD [130]. A further 16-week study in 
people with Type 2 diabetes found that those with poorer insulin sensitivity or preserved islet 
β-cell function at baseline experienced greater improvements in glycemic control with 
pioglitazone than with metformin [131]. Significant improvements versus placebo in insulin 
sensitivity, as measured using either the HOMA or the QUICKI, were also seen in a meta-
analysis of data from three placebo-controlled registration studies that included approximately 
1000 people with Type 2 diabetes [132]. Improvements versus placebo were seen for those 
treated with pioglitazone as monotherapy as well as among those who received pioglitazone 
in combination with a sulfonylurea or metformin [132]. A 32-week study in people with Type 
2 diabetes revealed potential differences between pioglitazone and metformin in terms of their 
ability to improve insulin sensitivity [133]. While both agents improved glycemic control, 
people treated with pioglitazone experienced more pronounced improvements in insulin 
sensitivity compared with those who received metformin monotherapy [133]. At study 
endpoint, HOMA insulin sensitivity was increased from baseline by 15% with pioglitazone 
(p<0.005), whereas there was no difference from baseline with metformin (−1%), with a 
significant between-group difference (p<0.05). 
 Studies comparing addition of rosiglitazone to existing metformin therapy versus 
uptitration of metformin show significantly greater improvement in HOMA insulin sensitivity 
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in the rosiglitazone groups [134–136]. Improvements in HOMA were also significantly better 
with the rosiglitazone/metformin combination compared with uptitrated metformin or 
rosiglitazone alone (62% versus 36% versus 36% respectively; all significant versus baseline)  
in a 32-week study of 468 drug-naïve patients with uncontrolled Type 2 diabetes [137]. 
Two 2-year studies have compared the effects on HOMA-%S, fasting serum insulin, 
C-peptide and insulin precursors of: 1) pioglitazone versus metformin when added to existing 
sulfonylurea therapy; and 2) pioglitazone versus gliclazide when added to existing metformin 
therapy [138]. Sustained improvements in glycemic control (HbA1c and FPG) with 
pioglitazone or metformin were accompanied by sustained improvements in fasting insulin 
and C-peptide levels, which translated to an improvement of HOMA-%S (7.1–11.8% with 
pioglitazone; 5% with metformin). Conversely, gliclazide was associated with increased 
fasting insulin and improvements in FPG that were not sustained and no change in HOMA-
%S. These data show that pioglitazone or metformin treatment produces long-term 
improvements in FPG and insulin sensitivity, most likely reflecting improved hepatic insulin 
sensitivity. 
As the mode of effect of metformin is generally considered to be a direct effect on HGO, at 
least in the fasting state, it is not surprising that metformin has consistently been demonstrated 
to cause a reduction in FPG [89]. If the action of thiazolidinediones is primarily to affect liver 
insulin sensitivity (either directly or indirectly), then they might also be expected to have a 
greater effect on FPG relative to postprandial plasma glucose, due to the liver’s predominant 
role in controlling FPG, compared with its shared role in controlling glucose disposal. At least 
some impact on postprandial glucose is still likely as, in Type 2 diabetes, the absolute 
postprandial levels of glycemia are mainly dependent upon HGO and absolute glucose 
disposal is generally unchanged compared with non-diabetics — rather it is just inappropriate 
for the overall levels of glycemia due to insulin insensitivity [139]. On the other hand, as the 
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greater proportion of glucose uptake in the fasting state in Type 2 diabetes is not insulin 
sensitive [13], an effect primarily on peripheral insulin sensitivity to increase peripheral 
glucose disposal should, for the most part, affect postprandial glucose. A review of recent 
clinical trials clearly demonstrates a consistent reduction in FPG with thiazolidinediones 
(Table 1), supporting a hepatic site of action [129,132,134,136,137,140–152]. 
 
Studies in people with other medical conditions 
Further support for a hepatic site of action for metformin and the thiazolidinediones is 
provided from studies in people conditions other than diabetes, including non-alcoholic fatty 
liver disease (NAFLD)/ non-alcoholic steatohepatitis (NASH), and polycystic ovary 
syndrome (PCOS), both of which are generally characterized by the presence of insulin 
insensitivity (a significant component of which has been shown specifically to be hepatic 
insulin insensitivity [153]), and lipodystrophy syndromes.  
 
Non-alcoholic fatty liver disease (NAFLD)/ non-alcoholic steatohepatitis (NASH) 
Insulin insensitivity appears to be the most reproducible predisposing factor for NAFLD, 
prompting trials of insulin-sensitizing drugs in this patient group [154]. Small trials with 
metformin or thiazolidinediones reveal improvements in measures of hepatic function in 
people with NAFLD or NASH [for review see 155]. Bugianesi and colleagues showed that 12 
months’ treatment with metformin in patients with NAFLD (n=110) significantly improved 
the chances of having a normal ALT compared with a prescriptive diet or vitamin E treatment 
[156]. Metformin also significantly improved HOMA insulin sensitivity compared with diet. 
A control biopsy of 17 metformin-treated patients also showed significant reductions in liver 
fat, necroinflammation, and fibrosis. In a study in 36 patients with NASH, metformin 
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significantly improved ALT, aspartate aminotransferase (AST), and HOMA compared with 
diet alone [157]. The first randomized, double-blind, placebo-controlled trial to examine the 
role of a thiazolidinedione (pioglitazone) in NASH (n=55) showed that pioglitazone treatment 
for 6 months significantly improved multiple metabolic and histological abnormalities 
compared with diet alone [158]. Hepatic insulin sensitivity was improved, ALT and AST 
levels were decreased, liver fat content reduced by 50%, hepatic inflammation reduced, and 
combined pathological score improved. Adiponectin levels significantly increased and were 
inversely correlated with the reduction in hepatic fat. The results of several small studies 
support these observations. In one study, troglitazone treatment over 3−6 months produced 
normalization of ALT in 7 of 10 participants and improved inflammation in 4 participants at 
follow-up [159]. In another study over 48 weeks, rosiglitazone treatment in 30 people 
improved insulin sensitivity and histological markers of NASH [160]. Finally, a 1-year study 
with pioglitazone in 18 NASH patients without diabetes also resulted in significant 
improvements in insulin sensitivity, serum ALT and histological features [161]. In addition, a 
small pilot study has shown that a combination of vitamin E and pioglitazone produces a 
greater improvement in NASH histology compared with vitamin E alone [162].  
 
Polycystic ovary syndrome [PCOS] 
Metformin is widely used off-label for the treatment of anovulation in women with PCOS and 
has been shown to improve insulin sensitivity and hormone patterns, as well as ovulation and 
pregnancy rates in numerous small trials [163]. In a recent large scale study, extended release 
metformin significantly improved HOMA insulin sensitivity, but did not appear to have any 
additional impact on fertility outcomes when added to the estrogen antagonist clomiphene 
[164]. The impact of metformin on HOMA in PCOS patients has been shown to persist over 4 
years of therapy [165]. Thiazolidinediones appear to have similar benefits to metformin in this 
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patient group, although experience is much more limited [166], Rosiglitazone treatment for 3 
months significantly improved HOMA insulin sensitivity in women with PCOS [167]. 
Treatment with pioglitazone (median 10 months) also significantly improved HOMA insulin 
sensitivity in women with PCOS not responding to metformin [168]. Tarkun and colleagues 
[169] showed significant decreases in CRP levels and improvements in HOMA insulin 
sensitivity with 12 months of rosiglitazone therapy in non-obese young women with PCOS. In 
a more recent placebo-controlled study, rosiglitazone significantly reduced CRP levels and 
ALT activity, and had beneficial effects on adiponectin and resistin levels in overweight 
women with PCOS [170, 171]. 
 
Lipoatrophy/lipodystrophy syndromes 
The use of antiviral therapy containing protease inhibitors in people with HIV is also 
associated with lipodystrophy, insulin resistance, and glucose intolerance [for review see 172. 
Although these patients have decreased subcutaneous fat, they have more intra-abdominal and 
liver fat compared with non-HIV controls and have elevated ALT [173]. In a small placebo-
controlled study in this patient group, rosiglitazone treatment for 24 weeks significantly 
decreased percent liver fat and normalized ALT [173]. Furthermore, in antiviral therapy 
lipodystrophy patients, PAI-1 concentrations, which correlate closely with increased liver fat 
(but not the size of other fat deposits) are decreased, together with a reduction in liver fat after 
24 weeks of rosiglitazone treatment [174]. In addition, rosiglitazone has been shown to 
increase adiponectin and decrease resistin levels in these patients [175]. An earlier study in 
patients with a range of non-antiviral-induced lipoatrophy and lipodystrophy syndromes 
showed that after 6 months of troglitazone therapy, there was a selective increase in 
subcutaneous adipose tissue and a significant reduction in the size of the liver, suggesting a 
shift in fat storage from the liver to the periphery [176]. A recent study suggests that both 
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rosiglitazone and metformin improve HOMA insulin sensitivity to a similar extent in this 
patient group [177]. 
 
Summary and Conclusions 
The processes governing glucose homeostasis in the liver, particularly those involved in 
insulin signalling, are complex and highly coordinated. It is clear that hepatic dysfunction 
(and HGO) is central to the pathogenesis of hyperglycemia in Type 2 diabetes, although the 
pathophysiological mechanisms underlying the dysfunction remain uncertain. It is most easily 
assessed as hepatic insulin insensitivity, and this remains a key target of glucose-lowering 
therapy. It is now clearly established that thiazolidinediones and metformin both improve 
hepatic insulin action and reduce HGO. Whereas metformin’s main mechanism of action in 
the liver appears to be a direct effect on HGO that may involve AMPK, multiple hepatic and 
extrahepatic mechanisms may be present for thiazolidinediones, including effects on 
adipokines (especially adiponectin), NEFA levels, and altered gene expression in hepatocytes 
(affecting gluconeogenesis and fat mobilization), Evidence from several sources, including 
knockout mice and clinical studies now supports a primary effect of thiazolidinediones in the 
liver. Whether this is mainly direct or indirect (via effects in adipose tissue and muscle) and 
the extent of the contribution from the hepatic component to overall glucose homeostasis 
remains to be clarified definitively. 
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Table 1 Components of glucose metabolism contributing to hyperglycemia 
Organ Manifestation 
Liver increased glucose output 
 non-suppressed glucose output 
 insulin insensitivity 
 lost sensitivity to hyperglycemia 
 lost hepatic autoregulation 
Skeletal muscle decreased glucose clearance 
 insulin insensitivity 
 glucose insensitivity  
 unchanged glucose uptake 
Non-insulin sensitive decreased glucose clearance 
[brain and others] glucose insensitivity 
 increased glucose metabolism  
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 Table 2 Change in FPG with thiazolidinediones in large-scale (n≥200), double-blind, 
randomised, controlled, ≥16 weeks’ duration studies  
 
Reference Study 
Duration 
(wk) 
Treatment 
Groups 
∆HbA1c  
(% change) 
∆FPG (% 
change) 
Bailey et al [2005] 24 Rosi+Met 
Met(uptitrated) 
-4.1 
-1.4 
-13.3 
-3.1 
Baksi et al [2004] 26  Rosi+Glic 
Glic 
-14.1 vs Glic 
— 
-29.1 vs Glic 
— 
Charbonnel et al [2005] 52 Pio 
Glic 
-16.1 
-16.1 
-21.6 
-17.9 
Einhorn et al [2000] 16 Pio+Met 
Pbo+Met 
-8.4 vs Pbo 
— 
-14.9 vs Pbo 
— 
Garber et al [2006] 24 Rosi+Met 
Glib+Met 
-13.1 
-17.9 
-25.0 
-24.5 
Hanefeld et al [2004] 52 Pio+SU 
Met+SU 
-13.7 
-15.3 
-17.8 
-20.0 
Herz et al [2003] 16 Pio[30] 
Pio[45] 
Pbo 
-10.7 
-11.8 
-2.7 
-15.7 
-18.6 
-1.1 
Kerenyi et al [2004] 26 Rosi+Glib 
Glib 
-11.5 
-1.8 
-22.3 
+2.1 
Kipnes et al [2000] 16 Pio[15]+SU 
Pio[30]+SU 
Pbo+SU 
-8.0 
-12.1 
+1.0 
-13.7 
-21.9 
+2.4 
Matthews et al [2004] 52 Pio+Met 
Glic+Met 
-11.3 
-11.8 
-16.1 
-15.0 
Pavo et al [2003] 32 Pio 
Met 
-15.1 
-17.4 
-25.9 
-22.6 
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Rosenstock et al [2002] 16 Trog+Nat 
Trog+Pbo 
Nat+Pbo 
Pbo 
-20.5 
-9.9 
-7.1 
+6.1 
-30.5 
-19.4 
+4.6 
+6.7 
Rosenstock et al [2006] 32 Rosi+Met 
Rosi 
Met 
-25.8 
-18.2 
-20.5 
-36.6 
-24.3 
-23.6 
Schernthaner et al [2004] 52 Pio 
Met 
-16.2 
-17.3 
-21.9 
-19.4 
Stewart et al [2006] 32 Rosi+Met 
Met(uptitrated) 
-7.1 
-5.3 
-17.8 
-10.7 
Tan et al [2004a] 52 Pio 
Glim 
-9.1 
-8.0 
-6.6 
+6.6 
Tan et al [2004b] 52 Pio 
Glib 
-6.0 
-4.7 
-6.6 
+1.9 
Weissman et al [2005] 24 Rosi+Met 
Met(uptitrated) 
-11.6 
-8.9 
-22.2 
-11.2 
Yale et al [2000] 24 Trog 
Pbo 
-14.6 vs Pbo 
— 
-20.9 vs Pbo 
— 
Glic=gliclazide; Glib=glibenclamide; Glim=glimepiride; Met=metformin; Nat=nateglinide; 
Pbo=placebo; Pio=pioglitazone; Rosi=rosiglitazone; SU=sulfonylurea; Trog=troglitazone 
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Fig. 1 Hepatic insulin insensitivity in Type 2 diabetes. Hepatic glucose output is increased, 
despite hyperglycemia [panel A; Jeng et al, 1994; open circles = control subjects; closed 
circles = people with Type 2 diabetes] and hyperinsulinemia [panel B; Groop et al, 1989; 
broken line = non-obese Type 2 diabetes; solid line = matched control subjects mean ± SEM 
*p<0.05, **p<0.01 versus control subjects]. 
A. 
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Fig. 2 Thiazolidinediones may improve many aspects of hepatic dysfunction through multiple 
mechanisms  
 
 
 
